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European Union’s tobacco products directive
Many questions remain about the influence of industry
Martin McKee professor of European public health
London School of Hygiene and Tropical Medicine, London WC1H 9SH, UK
On 8 October 2013, the European Union moved a step closer
to strengthening tobacco control whenmembers of the European
Parliament (MEPs) voted for a European Commission proposal
for a revised directive on tobacco products, albeit with extensive
amendments. The appointed rapporteur, Linda McAvan MEP,
will now seek agreement with representatives of the commission
and the Council of the European Union (comprising national
governments).
It is remarkable that the proposal has made it this far. The
tobacco industry did everything possible to derail it, with Philip
Morris spending up to €1.25m (£1.06m; $1.7m) in 2012 in
intensive lobbying,1 mostly directed at MEPs.2 However, the
legislation still faces many risks. The parliament, commission,
and council must agree on the text, and the council presidency
will rotate from Lithuania, whose health minister is a staunch
advocate of tobacco control, to Greece, where Philip Morris is
investing heavily in a new distribution facility.3
So what does the legislation currently propose? It builds on the
2001 Tobacco Products Directive that increased the size of
compulsory labels on cigarette packs and allowedmember states
to introduce graphic warnings.4 However, many of the
commission’s proposals have beenwatered down, whereas some
of the most effective, such as standardised packaging and bans
on point of sale displays, were removed earlier.
The proposal that pictorial warnings cover 75% of both sides
of packs was reduced to 65%, better than the industry’s goal of
50%. Moreover, the warning must be at the top of the pack and
not, as industry wanted, at the bottom, where it could easily be
hidden by display cases. Cigarettes will no longer be sold in
packs of 10, which are more affordable for children. Provisions
to increase traceability of cigarettes will be strengthened to
tackle smuggling, in which the industry has been complicit.5
However, the effectiveness of these provisions is
questionable—Interpol is supporting a system with known
weaknesses, developed after a $15m grant from Philip Morris.6
The earlier directive required additives simply to be listed. Now,
those that impart a flavour will be banned, except for menthol,
which will be permitted for another five years. This is a great
victory for the industry, which adds menthol to about 90% of
its products, even when not described.7 Menthol interacts with
nicotine to increase the impact of the first inhalation and reduces
the throat irritation experienced by novice smokers.8
Consequently, many products have been designed to maximise
these effects. The industry also benefits from the widespread
view that menthol cigarettes are healthier.9
The most contentious area is e-cigarettes. The commission
proposed treating them like any other nicotine delivery device
and regulating them as drugs, a view supported by many
governments, including that of the United Kingdom, after careful
review of the evidence. The parliament was, however, influenced
by intensive lobbying against this, although the meaning of the
alternative text is unclear. Now, “all nicotine containing
products” will be subject to the same restrictions on cross border
advertising and sponsorship as cigarettes. Although cigarette
brand names will be banned, the many flavourings, such as
bubble gum and cotton candy, which increase their appeal to
children, will not. However, the draft text goes on to urge
governments to “ensure that they can be made available as
widely as tobacco products,” reflecting unsubstantiated claims
that they are a “game changer” for smoking cessation.10 The
draft legislation fails to address the rapid growth in sales of
products designed to resemble real cigarettes as closely as
possible. This subterfuge is widely viewed as a way to
renormalise smoking, a key goal of those seeking to recruit child
smokers, and to counter some of the effects of smoking bans.11
Fortunately, nothing prevents governments from adopting more
effective legislation, such as standardised packaging, but much
needs to be done before a workable text is ready, and it is
unfortunate that so many opportunities have been missed.
However, this experience may bring other benefits. The co-chair
of the parliament’s public health committee has condemned
most MEPs for doing “the bidding of the tobacco industry,”11
focusing much needed attention on the role of industry lobbyists
in Brussels.
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